Surgery for Recurrent Glioblastoma (RESURGE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02394626|
Recruitment Status : Recruiting
First Posted : March 20, 2015
Last Update Posted : October 11, 2018
Patients with glioblastoma face a grim prognosis. Despite recent advancement in neurosurgical technology and neuro-oncology glioblastomas almost invariably progress or recur after a median of 4-8 months. The strategy to repeat tumor resection at recurrence in order to minimize tumor load and thus to facilitate subsequent second-line therapy has been shown to be feasible and safe.
However, evidence for a survival benefit of surgery for recurrent glioblastoma is scarce and relies entirely on retrospective analyses. While most retrospective analyses report an apparent survival benefit, an EORTC meta-analysis on second-line therapies found no survival difference in patients with or without surgery at recurrence. With regard to the risks and costs inherent to surgery for glioblastoma, a randomized controlled trial is required.
The purpose of the study is to compare the effect of craniotomy and tumor resection followed by adjuvant second-line therapy to no surgery followed by second-line therapy on overall survival, neurological status, and quality of life. Analysis of overall survival will be used to improve sample size estimation of a subsequent phase III trial for craniotomy and tumor resection of glioblastoma recurrence in cooperation with the EORTC.
|Condition or disease||Intervention/treatment||Phase|
|Glioblastoma||Procedure: Surgery followed by adjuvant second-line therapy Procedure: Second-line therapy alone||Phase 2|
Glioblastoma is a malignant, locally invasive brain tumor whose prognosis remains grim despite various intense treatment modalities. In the past, radical surgery was met with skepticism due to the aggressive infiltrative character of the tumor. However, an increasing number of retrospective studies over the last decade suggest a survival benefit for surgery. A recent post-hoc analysis of a randomized controlled trial on the use of the surgical adjunct 5-ALA reported a prolonged overall survival from 11.9 to 16.7 months (evidence level 2a) after more extensive resection. Thus, maximal safe resection has become a mainstay of treatment for newly diagnosed glioblastoma, followed by adjuvant radio-chemotherapy.
Glioblastoma almost invariably recurs after a median of 6.9 months, leaving but few options for further treatment. Recurrence of glioblastoma after surgery and concomitant adjuvant therapy represents an additional therapeutic challenge and may be treated with second-line pharmacotherapy. In addition, a second surgery may also be considered in highly selected patients.
The rationale for surgery - maximum safe resection - is to prolong survival through reduction of tumor load, and, maybe due to an increased efficacy of adjuvant treatment. However, surgery carries risks of complications, that may result in a decreased functional and survival outcome. The crucial question therefore is whether, to what extent, and at what costs in terms of neurological risks a second resection prolongs survival.
The primary objective of this randomized trial is to compare survival outcome after surgery followed by adjuvant second-line therapy to no surgery followed by second-line therapy in recurrent glioblastoma. An auxiliary objective to primary objective is to compare the survival outcomes of operated patients to control in the subgroups stratified by extent of resection: incomplete resection (non-CRET) vs complete resection (CRET).
Secondary objectives are: assessment of recruitment for all screened patients, comparison of progression-free survival between treatment arms, evaluation of crossover and comparison of patient quality of life between treatment arms.
Safety objectives are: to assess neurological deficits, local infections and morbidity associated to surgery and hospital stay after surgery and during follow-up.
All patients (≥18 years) with a radiological suspicion of first recurrence of glioblastoma are screened for this trial. Patients eligible for study participation are informed on the treatment options for recurrent glioblastoma (surgery followed by adjuvant second-line therapy, second-line therapy, or palliative therapy alone) by the center investigators. Patients randomized to the control group will receive second-line therapy according to local guidelines. Patients randomized to the interventional group will receive a craniotomy and resection of the tumor followed by adjuvant second-line therapy. Outcome will be measured at 3 months intervals.
Recruitment rate and reason for non-inclusion will be monitored.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||120 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||RESURGE - Randomized Controlled Comparative Phase II Trial on Surgery for Glioblastoma Recurrence|
|Study Start Date :||May 2015|
|Estimated Primary Completion Date :||October 2020|
|Estimated Study Completion Date :||October 2020|
Experimental: Surgery followed by adjuvant second-line therapy
Surgery followed by adjuvant second-line therapy
Procedure: Surgery followed by adjuvant second-line therapy
Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. However, some form of intra-operative resection control (iMRI or intra-operative fluorescence) and function control (electrophysiology) should be available to the surgeon and used when warranted.
Adjuvant second-line therapy:
Patients will be seen after surgery by the treating neurooncologist. Modalities of adjuvant second-line therapy are individually defined according to local guidelines and are not stipulated by study protocol.
Active Comparator: Second-line therapy alone
Second-line therapy alone
Procedure: Second-line therapy alone
Patients randomized to the non-surgical cohort receive second-line therapy according to local guidelines. Modalities thereof are not stipulated by study protocol.
- Overall survival from the date of inclusion [ Time Frame: From the date of inclusion until death/end of study, assessed up to 5.7 years ]
- Recruitment rate for all screened patients [ Time Frame: Screening and inclusion ]
- Progression-free survival [ Time Frame: From the date of inclusion until the date of objective progression or the date of patient's death, whichever occurs first, assessed up to 5.7 years ]
- Morbidity of surgery [ Time Frame: Every 3 months up to 2 years or until death, assessed up to 5.7 years ]
- Total number of days spent at home after recurrence [ Time Frame: From the date of inclusion until death/end of study, assessed up to 5.7 years ]
- Total number of days spent outside home after recurrence [ Time Frame: From the date of inclusion until death/end of study, assessed up to 5.7 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02394626
|Contact: Annetta Redmann||+41 31 632 95 email@example.com|
|Contact: Nicole Söll||+41 31 63 2 31 6||Nicole.Soell@insel.ch|
|Contact: Christian Freyschlag, MD firstname.lastname@example.org|
|Contact: Johannes Kerschbaumer, MD Johannes.email@example.com|
|Helios Klinikum Erfurt||Recruiting|
|Erfurt, Germany, 99089|
|Contact: Rüdiger Gerlach, MD firstname.lastname@example.org|
|Universitätsklinikum Gießen und Marburg||Recruiting|
|Giessen, Germany, 35392|
|Contact: Marco Stein, MD Marco.Stein@neuro.med.uni-giessen.de|
|Universitätsmedizin der Johannes Gutenberg-Universität Mainz||Recruiting|
|Contact: Mirjam Renovanz, MD email@example.com|
|Münster, Germany, 48149|
|Contact: Benjamin Brokinkel firstname.lastname@example.org|
|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta||Recruiting|
|Milano, Italy, 20133|
|Contact: Francesco Di Meco email@example.com|
|Contact: Cecilia Casali firstname.lastname@example.org|
|Aarau, Switzerland, 5001|
|Contact: Serge Marbacher, MD +41 62 838 66 2 email@example.com|
|Basel, Switzerland, 4031|
|Contact: Dominik Cordier firstname.lastname@example.org|
|Dep. of Neurosurgery, Bern University Hospital||Recruiting|
|Bern, Switzerland, 3010|
|Principal Investigator: Philippe Schucht|
|Dep. of Neurosurger, Hôpitaux Universitaires de Genève||Recruiting|
|Geneva, Switzerland, 1205|
|Principal Investigator: Shahan Momjian|
|Dep. of Neurosurgery, Centre hospitalier universitaire vaudois||Recruiting|
|Lausanne, Switzerland, 1011|
|Principal Investigator: Andreas Hottinger|
|Ospedale Regionale di Lugano||Recruiting|
|Lugano, Switzerland, 6900|
|Contact: Michael Reinert, MD email@example.com|
|Luzern, Switzerland, 6000|
|Contact: Karl Kothbauer firstname.lastname@example.org|
|Dep. of Neurosurgery, University Hospital of Zurich||Recruiting|
|Zurich, Switzerland, 8091|
|Principal Investigator: Luca Regli|
|Principal Investigator:||Philippe Schucht, Prof. Dr. med.||Dep. of Neurosurgery, Inselspital Bern|